Robert J. Bitterman

Insider Reports History

Reporting-owner location: Westborough, MA
Latest reporting-owner signature: /s/ Lisa C. Carson, Attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert J. Bitterman

Form 4 holding Chairman, Pres. & CEO, Director

Phio Pharmaceuticals Corp.

Security class: Common Stock, $.0001 par value
Shares / value: 364,871
Estimated value: $375,415
Report date: 22 Sep 2026
Price: $1.03
Ownership: Direct

Insider Reports Filed by Robert J. Bitterman

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 22 Sep 2026
Transactions: 1
Transaction value: +$2,058
Accepted by SEC: 23 Sep 2026, 16:01
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 11 Sep 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Sep 2026, 16:00
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 18 Aug 2026
Transactions: 1
Transaction value: +$10,600
Accepted by SEC: 19 Aug 2026, 16:01
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 26 Jun 2026
Transactions: 1
Transaction value: +$9,900
Accepted by SEC: 29 Jun 2026, 16:02
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 05 Feb 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Feb 2026, 07:56
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 31 Dec 2025
Transactions: 1
Transaction value: +$5,150
Accepted by SEC: 02 Jan 2026, 16:05
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 23 Dec 2025
Transactions: 1
Transaction value: +$5,100
Accepted by SEC: 29 Dec 2025, 08:10
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 21 Nov 2025
Transactions: 1
Transaction value: +$5,700
Accepted by SEC: 24 Nov 2025, 12:54
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 18 Nov 2025
Transactions: 1
Transaction value: +$6,350
Accepted by SEC: 19 Nov 2025, 12:47
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 11 Sep 2025
Transactions: 2
Transaction value: -$9,538
Accepted by SEC: 15 Sep 2025, 08:28
Role: Chairman, Pres. & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 10 Jun 2025
Transactions: 1
Transaction value: +$4,840
Accepted by SEC: 11 Jun 2025, 17:00
Role: Chairman, Pres & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 09 Jun 2025
Transactions: 1
Transaction value: +$4,125
Accepted by SEC: 10 Jun 2025, 16:43
Role: Chairman, Pres & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 21 May 2025
Transactions: 2
Transaction value: +$7,446
Accepted by SEC: 23 May 2025, 09:04
Role: Chairman, Pres & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 11 Sep 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Sep 2024, 14:59
Role: Chairman, Pres & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 07 Jun 2024
Transactions: 1
Transaction value: +$740
Accepted by SEC: 11 Jun 2024, 17:00
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 06 Jun 2024
Transactions: 1
Transaction value: +$750
Accepted by SEC: 10 Jun 2024, 17:00
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 26 Feb 2024
Transactions: 1
Transaction value: +$2,275
Accepted by SEC: 27 Feb 2024, 16:42
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 20 Feb 2024
Transactions: 1
Transaction value: -$1,371
Accepted by SEC: 22 Feb 2024, 19:00
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 01 Oct 2023
Transactions: 1
Transaction value: -$1,385
Accepted by SEC: 03 Oct 2023, 19:00
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 30 Jun 2023
Transactions: 2
Transaction value: +$5,720
Accepted by SEC: 05 Jul 2023, 18:00
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 20 Feb 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Feb 2023, 18:00
Role: President & CEO, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 14 Dec 2022
Transactions: 1
Transaction value: +$780
Accepted by SEC: 15 Dec 2022, 16:00
Role: Interim Executive Chairman, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 07 Dec 2022
Transactions: 1
Transaction value: +$780
Accepted by SEC: 08 Dec 2022, 15:30
Role: Interim Executive Chairman, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 05 Dec 2022
Transactions: 1
Transaction value: +$860
Accepted by SEC: 06 Dec 2022, 15:30
Role: Interim Executive Chairman, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 25 Nov 2022
Transactions: 2
Transaction value: +$1,136
Accepted by SEC: 29 Nov 2022, 15:30
Role: Interim Executive Chairman, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 16 Nov 2022
Transactions: 1
Transaction value: +$1,750
Accepted by SEC: 16 Nov 2022, 16:06
Role: Interim Executive Chairman, Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 01 Oct 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Oct 2022, 20:01
Role: Director
Next action: Open filing details

4 PHIO

Phio Pharmaceuticals Corp.

Report period: 15 Feb 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 16 Feb 2022, 18:59
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .